That is very interesting, you have a great understanding of the science, do you see the Harvard/Biogen approach as directly competing for the same patient cohort as PYC? Or smaller/greater? Their not quite as explicit as PYC is on number of patients that will benefit.
Could PYC be where Nightstar is in 2-3 years (45c) if we can rival them in having in the stable “two potentially first-in-class mid- to late-stage clinical assets as well as preclinical programs”?
Or more.... if VP-001 is applied successfully to the 6 other inherited retinal diseases + Negoro degenerative + genetic liver diseases...
I just don’t know how we are going to fund all these opportunities in parallel - do you think a cap raise is on the cards for 2020?
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.20 |
Change
0.050(4.35%) |
Mkt cap ! $699.9M | |||
| Open | High | Low | Value | Volume |
| $1.16 | $1.21 | $1.13 | $387.7K | 327.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2000 | $1.12 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.20 | 25000 | 1 |
View Market Depth
| Last trade - 16.10pm 23/06/2025 (20 minute delay) ? |
| PYC (ASX) Chart |